INTRODUCTION

Propofol is an anesthetic agent used for induction and main-
The purpose of this study was to investigate the relations between the effect-site concentration (Ce) of propofol and the degrees of sedation and airway obstruction in patients with OSAHS receiving the sedative through a target-controlled infusion (TCI) device.

**MATERIALS AND METHODS**

This study was approved by the Yonsei University Health System Ethics Committee, and informed consent was obtained from all patients before including them in the study. Twenty-five participants, all above 20 years of age and with an American Society of Anesthesiologists classification I or II, were sedated in order to perform drug-induced sleep endoscopy, i.e., assessing the cause of the apnea and snoring by pharmacologically inducing the patient into a light sleep and performing flexible endoscopy of the upper airway. The patients presented subjective symptoms such as snoring, daytime sleepiness, morning headache, sleep disturbance, fatigue, and an apnea-hypopnea index (AHI) >5 recorded by unattended polysomnography [8-channel polygraphy: SpO2, heart rate (HR), flow cannula sensor, actometer, abdominal & thoracic external effort-sensor, electrooculogram; MAP Poly-MESAM, Medicair, Milano, Italy]. OSAHS was categorized as mild (AHI: 5–15), moderate (AHI: 15–30), and severe (AHI: >30), as assessed by polysomnography. Patients were excluded from the study if they refused to participate or had hepatic, renal, or pulmonary disease; a history of chronic drug use with the potential to affect the central nervous system; a history of adverse drug reactions; or a history of heart block. Patients with impaired hearing, neurological deficits, or a Glasgow Coma Scale score under 15 were also excluded.

After arrival at the operating room, each patient’s electrocardiogram, peripheral oxygen saturation (SpO2), non-invasive arterial pressure, and bispectral index (BIS; BIS® monitor, Aspect medical Systems, Natick, MA, USA) were monitored and recorded at 5-min intervals throughout the whole procedure. Oxygen was given to the patients at 5 L/min via a facemask and nasal cannula. Hartmann’s solution of 4 mL/kg/hr was administered until all procedures ended. The temperature and humidity of the operating room were maintained at 22–24°C and 60%, respectively.

As an antisialagogue, 0.1 mg glycopyrrolate was injected intravenously. After confirmation of stable vital signs (<10% of baseline mean arterial pressure (MAP) and HR), sedation was induced by 2% propofol (Fresofol 2%TM; Fresenius Kabi, Austria) using a commercial TCI pump (Orchestra® Base Primea; Fresenius Vial, France). Operation of the pump was based on the pharmacokinetic model reported by Schnider, et al. The initial Ce of propofol was 0.5 μg/mL, and the Ce was increased at a rate of 0.1 μg/mL every 5 minutes by one anesthesiologist. The degrees of sedation and airway obstruction, MAP, HR, respiratory rate, SpO2, and BIS score were assessed and recorded by another anesthesiologist who was not aware of the propofol Ce just before it was increased for the next step. The degree of sedation was evaluated based on the Observer’s Assessment of Alertness/Sedation (OAA/S) scoring system, and airway obstruction was assessed using a four-category scale (Table 1). When the MAP was lower than 60 mm Hg or systolic arterial pressure was lower than 90 mm Hg, 4 mg ephedrine was injected intravenously, and when HR dropped below 50 beats/min, 0.5 mg atropine was injected intravenously. When bradypnea or hypoxia (SpO2 below 90%) occurred, oxygen, and ventilatory support were provided to the patients immediately via jaw thrust. When the OAA/S score reached 5, we completed the study, and a flexible nasal endoscopy was then performed to confirm apneic events and correlate them with pharyngeal collapse patterns. If the endoscopy failed due to patient movement, the Ce of propofol was gradually increased by 0.1 μg/mL until the procedure was successful.

The probability (P) of a given level of effect (sedation or airway obstruction) was related to propofol Ce using the following sigmoidal equation.

\[
P_y(\text{effect} \geq m) = \frac{Ce_y}{Ce_y + Ce_{50(m)}}
\]

In this equation, \(P_y(\text{effect} \geq m)\) is the probability for the \(i^{th}\) individual that the \(j^{th}\) effect score is equal to or greater than (i.e., “deeper than”) a given discrete level (m). \(Ce_y\) is propofol Ce for the \(i^{th}\) individual at the \(j^{th}\) observation. \(Ce_{50(m)}\) is the steady-state Ce associated with 50% probability corresponding to the \(i^{th}\) patient, and \(\lambda_i\) is the steepness of the probability versus the concentration curve corresponding to the \(i^{th}\) patient.

The complete model for each of the two response studies consisted of four and three separate models, one for each of the following scores: 2, 3, 4, and 5 for sedation and 2, 3, and 4 for airway obstruction, respectively. Sedation and airway obstruction scores of 1 were not included, as these were baseline scores measured before propofol was applied. Model parameters are a subject of further study.
were estimated using the function "LIKELIHOOD LAPLACE METHOD=conditional" in Nonlinear Mixed Effects Modeling (NONMEM) software (version VII; GloboMax, Hanover, MD, USA). For each analysis, NONMEM computed the minimum value of the objective function, a statistic that was proportional to the negative of twice the log likelihood of the data. The inter-individual random variability of each $Ce_{50}$ was modeled using a log-normal model, whereas the inter-individual random variability of $\gamma$ was fixed at zero. After obtaining the population base model, a forward inclusion and backward elimination approach was used in consecutive NONMEM runs to determine the relevant covariates among all covariates [age, sex, height, weight, AHI, and body mass index (BMI)]. A covariate was considered significant if its inclusion lowered the minimum value of the objective function by at least 3.85 points. The difference in the minimum value of the objective function between two nested models approximately follows a chi-square distribution and could therefore be used to investigate statistical significance [chi-square statistics equaled 3.84 at the level of significance ($p<0.05$), with one degree of freedom]. A non-parametric bootstrap procedure was performed for internal validation using Perl-speaks-NONMEM (PsN) (version 3.6.2, http://psn.sourceforge.net), and the original data set was randomly sampled to generate 2000 bootstrap replicates. We obtained the 95% confidence intervals of the nonparametric bootstrap replicates and compared final model parameter estimates with them.

**RESULTS**

Twenty-five patients who met the selection criteria were studied. Demographics of the enrolled patients are summarized in Table 2. Relations between propofol $Ce$ and the observed sedation and airway obstruction scores are shown in Fig. 1. Increments in propofol $Ce$ were associated with increased depth of sedation and airway obstruction (Fig. 1) and decreased values of BIS (Fig. 2). The sedation and airway obstruction effects were best described with a sigmoidal Emax model using propofol $Ce$. The estimated model parameters of the ultimately selected pharmacodynamic model and bootstrap estimates for each level of sedation and airway obstruction are summarized in Table 3. Based on our observations, all sedation- and airway obstruction-related parameters were estimated with adequate precision (relative standard error <50%) and were also reli-

**Table 2.** Demographics and General Characteristics of the Patients

| Clinical variables                  | Data values |
|------------------------------------|-------------|
| Sex (male/female)                  | 21/4        |
| Age (yrs)                          | 47.8±10.1   |
| Height (cm)                        | 168.1±7.3   |
| Weight (kg)                        | 75.3±12.0   |
| Body mass index (kg/m$^2$)         | 26.5±2.9    |
| Apnea-hypopnea index               | 42.4±21.5   |

Data are presented as mean±SD or as absolute numbers.

**Fig. 2.** The relation between propofol effect-site concentration and the observed bispectral index (BIS). The scattered dots are the raw data of BIS observed for all patients.
able, as they were within the 95% confidence intervals of the bootstrap estimates. The predicted $C_{50(m)}$ values corresponding to sedation scores (m) ≥2, 3, 4, and 5 were 1.61, 1.78, 1.91, and 2.17 μg/mL, respectively. The predicted $C_{50(m)}$ values corresponding to airway-obstruction scores (m) ≥2, 3, and 4 were 1.53, 1.64, and 2.09 μg/mL, respectively. Significant correlations were found between AHI and $C_{50(4)}$ for airway obstruction with a negative slope ($p<0.0001$) and AHI and BMI with a positive slope ($p<0.0001$), as shown in Fig. 3. The pharmacodynamic model including AHI significantly improved the performance of the base model based on the likelihood ratio test, decreasing the minimum value of the objective function from 507.0 to 501.4 ($p=0.018$). Considering that AHI was the only factor that showed correlation with propofol $C_{50(4)}$ for airway obstruction, we included this as a covariate in our model (Table 3).

**DISCUSSION**

In this study, we obtained the propofol $C_e$ for each sedation level.
Propofol-Induced Sedation and Airway Obstruction

and airway-obstruction score in patients with OSAHS and found that the AHI was a significant covariate of $C_{50}$ in the dynamic relationship between propofol $Ce$ and severe airway obstruction. Our study is the first clinical investigation in which pharmacodynamic modeling of sedation and airway obstruction in patients with OSAHS has been evaluated.

OSAHS is characterized by repetitive pharyngeal collapse during sleep, a process that constricts the pathway for airflow and causes periods of airflow reduction or cessation and a consequent reduction in blood oxygen levels. In the clinic, OSAHS is diagnosed using polysomnography and is defined by an AHI of five or more episodes per hour. Doses or concentrations of anesthetic drugs used for sedation need to be reduced for the safety of patients with sleep apnea. However, no studies have confirmed the relationship between the kinetics of sedative drugs and the degrees of sedation and airway obstruction in these patients. It would be clinically advantageous if the appropriate $Ce$ of propofol for each level of sedation and airway obstruction could be predicted and applied. A nonlinear dynamic model was chosen to describe the relationship between propofol $Ce$ and sedation and airway-obstruction scores, as the data were expected to fit a sigmoid slope.

Based on our results, increments in propofol $Ce$ were associated with increased depth of sedation and severity of airway obstruction. However, the differences between the predicted $C_{50}$ values for each level of sedation were small (about 0.1–0.3 $\mu$g/mL), and the $\lambda$ values for each probability curve of sedation were relatively high ($\geq12.8$). These model parameters for sedation indicate that unwanted deep sedation or inadequate sedation might easily happen. Thus, $Ce$ needs to be carefully titrated to achieve a certain level of sedation that is consistent with the known narrow therapeutic range of propofol. 

Given that our pharmacodynamic model was developed on the basis of data collected when using propofol alone without premedication or analgesics, propofol $Ce$ should be reduced to avoid oversedation when other drugs, which may have synergistic effects on sedation, are concurrently administered.

Special attention should be paid to the maintenance of airway patency during sedation in OSAHS patients, as $C_{50}$ values for snoring or severe airway obstruction were not distinctively different from the $C_{50}$ values for moderate sedation from a clinical point of view. There were no data available for healthy individuals without OSAHS that we could use for comparison. When we compared our results to the findings of Fábregas, et al., we found that our $C_{50}$ value (1.64 $\mu$g/mL) for snoring was lower than their reported $C_{50}$ value (2.98 $\mu$g/mL) for patients with Parkinson disease. It is commonly expected that patients with central nervous system dysfunction might be more sensitive to the hypnotic effect of propofol than healthy individuals. However, the airway of patients with OSAHS proved to be more

Fig. 4. Probability curves for propofol effect-site concentration versus each level of sedation (A) and airway obstruction (B). m, discrete level of sedation or airway obstruction.

Fig. 5. The curves are the fits resulting from a simulation by the pharmacodynamic model after adjustments for AHI score for propofol effect-site concentration versus severe airway obstruction. AHI, apnea-hypopnea index.
vulnerable to propofol than that of patients with Parkinson disease. Moreover, their pharmacokinetic values based on Marsh, et al. might be somewhat different from our pharmacokinetic values based on Schnider, et al.8

Sedation with propofol changes the macroarchitecture of sleep, and sedation-induced sleep does not seem to correlate well with natural sleep based on previous studies,18,19 although there is an ongoing debate concerning this. Our finding is meaningful in that the AHI, evaluated during natural sleep, proved to be a good covariate for severe airway obstruction during propofol sedation. The simulated propofol Ce0 for severe airway obstruction in a patient with an AHI of 70 is around three fourths of that in a patient with an AHI of 10. In patients with an AHI of 70, the propofol Ce0 for severe airway obstruction was similar to the propofol Ce0 for OAA/S3 sedation (1.81 μg/mL and 1.78 μg/mL, respectively), suggesting that these patients are at risk of having severe airway obstruction even during moderate sedation. Patients with high AHI values are more susceptible to airway obstruction and need more attention during propofol-induced sedation.

Obesity is associated with a 12- to 30-fold increased risk of OSAHS relative to the normal population, and OSAHS is found in 40% of obese females and 50% of obese males.20 BMI representing the severity of obesity correlated well with AHI in our study, confirming the findings of a previous report in which it was found to be an independent risk factor for snoring in Chinese women.21 Hence, we expected that BMI would be a potential covariate and could explain the interpatient variability in pharmacodynamic modeling for airway obstruction; however, the severity of obesity did not prove to be a significant covariate. One explanation for this outcome might be that there were only two obese patients with a BMI value higher than 30, while the average AHI of the population was relatively high.

The limitations of our study included our lack of permission to take blood samples to measure propofol concentration and our assumption that the Schnider model adequately characterized the patient population that we studied. Our results should thus be interpreted with caution, as the parameters of the pharmacodynamic model are dependent on the selected pharmacokinetic model. While the Schnider model is not perfect, it has fewer limitations than other pharmacokinetic models for propofol and therefore has the potential to become the recommended model to use when testing TCI.

We conclude that increments in propofol Ce are associated with increased depth of sedation and airway obstruction when determining the narrow therapeutic range of propofol in patients with OSAHS. AHI significantly affects the pharmacodynamic relationship between propofol Ce and severe airway obstruction. Propofol Ce for severe airway obstruction can be predicted for individual OSAHS patients with different AHI values, and patients with high AHI values need more attention in order to maintain airway patency during propofol-induced sedation.

ACKNOWLEDGEMENTS

This work was conducted in the department of Anesthesiology and Pain Medicine, Severance Hospital, Seoul, Korea. Support was provided only from departmental sources.

REFERENCES

1. Skues MA, Pryys-Roberts C. The pharmacology of propofol. J Clin Anesth 1989;1:387–400.
2. Fábregas N, Rapado J, Gambús PL, Valero R, Carrero E, Salvador L, et al. Modeling of the sedative and airway obstruction effects of propofol in patients with Parkinson disease undergoing stereotactic surgery. Anesthesiology 2002;97:1378-86.
3. Eastwood PR, Platt PR, Shepherd K, Maddison K, Hillman DR. collapsibility of the upper airway at different concentrations of propofol anesthesia. Anesthesiology 2005;103:470-7.
4. Sundaram S, Bridgman SA, Lim J, Lasserson TJ. Surgery for obstructive sleep apnoea. Cochrane Database Syst Rev 2005:CD001004.
5. Benumof JL. Creation of observational unit may decrease sleep apnoea risk. APSF Newsletter 2002;17:39.
6. Young T, Peppard PE, Gottlieb DJ. Epidemiology of obstructive sleep apnea: a population health perspective. Am J Respir Crit Care Med 2002;165:1217-39.
7. Schnider TW, Minto CE, Gambús PL, Andresen C, Goodale DB, Shafer SL, et al. The influence of method of administration and covariates on the pharmacokinetics of propofol in adult volunteers. Anesthesiology 1998;88:1170-82.
8. Schnider TW, Minto CE, Shafer SL, Gambús PL, Andresen C, Goodale DB, et al. The influence of age on propofol pharmacodynamics. Anesthesiology 1999;90:1502-16.
9. Chernik DA, Gillings D, Laine H, Hendler J, Silver JM, Davidson AB, et al. Validity and reliability of the Observer’s Assessment of Alertness/Sedation Scale: study with intravenous midazolam. J Clin Psychopharmacol 1990;10:244-51.
10. Collop NA, Anderson WM, Boehlecke B, Claman D, Goldberg R, Gottlieb DJ, et al. Clinical guidelines for the use of unattended portable monitors in the diagnosis of obstructive sleep apnea in adult patients. Portable Monitoring Task Force of the American Academy of Sleep Medicine. J Clin Sleep Med 2007;3:737-47.
11. Dhomner G, Combes X, Leroux B, Duvaldestin P. Postoperative obstructive apnoea. Anesth Analg 1999;89:762-7.
12. Chung F, Crago RR. Sleep apnoea syndrome and anaesthesia. Can Anaesth Soc J 1982;29:439-45.
13. Krauss B, Green SM. Sedation and analgesia for procedures in children. N Engl J Med 2000;342:938-45.
14. Jung M, Hofmann C, Kiesslich R, Brackertz A. Improved sedation in diagnostic and therapeutic ERCP: propofol is an alternative to midazolam. Endoscopy 2000;32:233-8.
15. Olmos M, Ballester JA, Vidarte MA, Elizalde JL, Escobar A. The combined effect of age and premedication on the propofol requirements for induction by target-controlled infusion. Anesth Analg 2000;90:1157-61.
16. McClune S, McKay AC, Wright PM, Patterson CC, Clarke RS. Synergistic interaction between midazolam and propofol. Br J Anaesth 1992;69:249-5.
17. Marsh B, White M, Morton N, Kenny GN. Pharmacokinetic model driven infusion of propofol in children. Br J Anaesth 1991;67:41-8.
18. Rabelo FA, Küpper DS, Sander HH, Fernandes RM, Valera FC, Polysomnographic evaluation of propofol-induced sleep in patients with respiratory sleep disorders and controls. Laryngoscope
Propofol-Induced Sedation and Airway Obstruction

19. Rabelo FA, Braga A, Küpper DS, De Oliveira JA, Lopes FM, de Lima Mattos PL, et al. Propofol-induced sleep: polysomnographic evaluation of patients with obstructive sleep apnea and controls. Otolaryngol Head Neck Surg 2010;142:218-24.

20. Kyzer S, Charuzi I. Obstructive sleep apnea in the obese. World J Surg 1998;22:998-1001.

21. Li QY, Huang SG, Li M, Liu JL, Wan HY. BMI is an independent risk factor for snoring in Chinese women aged over 30 years. Sleep Breath 2009;13:289-93.

22. Masui K, Upton RN, Doufas AG, Coetzee JI, Kazama T, Mortier EP, et al. The performance of compartmental and physiologically based recirculatory pharmacokinetic models for propofol: a comparison using bolus, continuous, and target-controlled infusion data. Anesth Analg 2010;111:368-79.